High Thrombosis Risk:
- CHA2DS2-VASc score > 7
- Mitral Valve Prosthesis
- Caged-ball or tilting-disc Aortic Valve (Bileaflet Aortic Valve Prosthesis is low risk)
- Stroke or Transient Ischemic Attack within 6 months
- Rheumatic valvular heart disease
- Recurrent idiopathic VTE
- Venous Thromboembolism within 3 months
- Venous Thromboembolismof any duration with severe thrombophilia (eg, homozygous factor V Leiden or positive antiphospholipid antibodies)
- Cancer-associated thrombosis
Low Thrombosis Risk:
- CHA2DS2-VASc score < 4
- Bileaflet aortic valve prosthesis
- Provoked Venous Thromboembolism > 3months
- Venous Thromboembolism at least 3 mo, with/without nonsevere thrombophilia (eg, heterozygous Factor V Leiden)
Reference:
Patel, Indravadan J., et al. “Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions-Part II: Recommendations: Endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe.” Journal of vascular and interventional radiology: JVIR (2019). https://www.ncbi.nlm.nih.gov/pubmed/31229333
Suggested Link:
https://articl.net/resource/interventional-radiology-medications